ClinicalTrials.gg
CompletedNCT02950454Updated Oct 25, 2017

The Effect of High Intensity Interval Training on Cardiovascular Fitness in People With Progressive Multiple Sclerosis.

An interventional study of High intensity interval training and Continuous moderate exercise in Multiple Sclerosis, Progressive, sponsored by University of Glasgow. Completed at 1 site in United Kingdom. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-10-25.

Sponsored by University of Glasgow · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a pilot trial to explore the cardiovascular of eight weeks of twice weekly high intensity interval training in people with progressive multiple sclerosis. A control group of people with progressive multiple sclerosis will undergo continuous moderate intensity exercise, twice weekly for 8 weeks.

Read the detailed description

This is a pilot trial to explore the cardiovascular of eight weeks of twice weekly high intensity interval training in people with progressive multiple sclerosis. A control group of people with progressive multiple sclerosis will undergo continuous moderate intensity exercise, twice weekly for 8 weeks.

The training program will entail 6x1.5 minute intervals working at 80-95% heart rate max on a cycle ergometer. Each interval will be interspersed with 1.5 minutes of working rest at a light resistance of the participant's choosing.

The continuous moderate intensity exercise program will entail 20 minutes on a cycle ergometer working at 60-70% heart rate max.

02

Conditions studied

  • Multiple Sclerosis, Progressive

Keywords

  • Progressive Multiple Sclerosis
  • Rehabilitation
  • Exercise
03

In context

Multiple Sclerosis, Chronic Progressive

242 studies on the registry are indexed under Multiple Sclerosis, Chronic Progressive; 55 are open to participants now.

This study's enrollment of 12 is below the median of 51 across 189 interventional studies indexed under Multiple Sclerosis, Chronic Progressive.

Browse Multiple Sclerosis, Chronic Progressive studies →

Lead sponsor

University of Glasgow is the lead sponsor of 145 studies on the registry; 21 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed with a progressive form of MS
  • Aged 18 years or older
  • Known to members of staff of the MS service NHS Ayrshire \& Arran
  • Ability to attend Douglas Grant Rehabilitation centre twice a week for eight weeks
  • EDSS 4-6.0
  • Able to cycle on ergometer

Exclusion criteria

Exclusion Criteria:

  • A relapse of symptoms requiring treatment within the past three months.
  • A respiratory condition that would be exacerbated by high intensity exercise including but not limited to: chronic obstructive pulmonary disorder, uncontrolled or poorly controlled asthma.
  • Uncontrolled high pressure at screening (>190/100 mmHg)
  • Cognitive impairment affecting ability to understand instructions as noted in patient's notes.
  • Currently engaging in another research trial for their MS or that may affect their physiological or cardiovascular outcomes
  • Weighing more than 110 kg (weight limit of ergometer)
  • Any pathology or medical intervention that would preclude high intensity exercise, maximal exertion testing or could attenuate the cardiovascular effect of exercise including but not limited to: unstable angina; diabetes; peripheral vascular disease or intermittent claudication; having a pace maker or medicine pump; surgical clips; having another neurological condition other than MS; and pregnancy. To be established from patient's notes and at screening session.
  • A serious cardiovascular event in the past year including but not limited to: transient ischaemic attack, cerebrovascular event and myocardial infarction.
  • Taking any of the following medication: beta blockers; vasodilators; ACE inhibitors; diuretics or any other medication that could cause exercise induced hypotension; hypoglycaemic insulin; metformin or other oral insulin medicine.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Intervention

    8 weeks of twice weekly high intensity interval training. Session protocol: 2 minute warm up at nominal resistance on cycle ergometer, 6 six intervals of 80-95% heart rate max interspersed with 6 intervals of 1.5 minute working rest. Then 3 minutes cool down.

    Other: High intensity interval training

  • Active comparator
    control

    8 weeks of twice weekly continuous moderate intensity exercise. Session protocol: 2 minutes warm up at nominal resistance on cycle ergometer, 20 minutes at 60-70% heart rate max. Then 3 minutes cool down.

    Other: Continuous moderate exercise

Interventions

  • OtherHigh intensity interval training

    1.5 min intervals at 80-95% heart rate max on cycle ergometer 1.5 min intervals at nominal resistance on cycle ergometer

  • OtherContinuous moderate exercise

    20 min at 60-70% heart rate max on cycle ergometer

06

What researchers measure

Primary outcomes

  1. heart rate max

    Maximal heart rate elicited during a maximal exertion test

    Time frame: 8 weeks

Secondary outcomes

  1. Resting blood pressure

    Time frame: 8 weeks

  2. Resting heart rate

    Time frame: 8 weeks

  3. Brain derived neurotrophic factor

    Hormone important for brain growth and protection

    Time frame: 8 weeks

  4. Lactate

    Waste materials from exercise in blood

    Time frame: 8 weeks

  5. Lipoprotein profile

    Indication of how much good and how much bad cholesterol is in blood

    Time frame: 8 weeks

  6. MSIS-29 version 2

    Questionnaire giving physical and psychological impact of MS

    Time frame: 8 weeks

  7. Hospital anxiety and depression scale

    Questionnaire giving a score of depression and anxiety

    Time frame: 8 weeks

  8. Timed 25 foot walk test

    Measure of walking speed

    Time frame: 8 weeks

  9. Symbol digit modalities test

    Measure of mental processing speed

    Time frame: 8 weeks

  10. Fatigue severity scale

    Questionnaire which gives measure of fatigue.

    Time frame: 8 weeks

07

Study locations

1 site
  • The University of Glasgow
    Glasgow, G12 8LL, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 25, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02950454
Collaborators
NHS Ayrshire and Arran, AKM
Responsible party
Evan Campbell (PhD Student, University of Glasgow) — Principal investigator
First posted
Nov 1, 2016
Start date
Jan 2017
Primary completion
Sep 2017
Completion
Sep 2017
Last update
Oct 25, 2017

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion